as 05-20-2024 4:00pm EST
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Founded: | 2005 | Country: | United States |
Employees: | N/A | City: | WATERTOWN |
Market Cap: | 22.7M | IPO Year: | 2020 |
Target Price: | $4.50 | AVG Volume (30 days): | 3.0M |
Analyst Decision: | Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.20 | EPS Growth: | N/A |
52 Week Low/High: | $0.35 - $6.79 | Next Earning Date: | 04-30-2024 |
Revenue: | $1,680,000 | Revenue Growth: | 28.74% |
Revenue Growth (this year): | -9.69% | Revenue Growth (next year): | -43.35% |
LYRA Breaking Stock News: Dive into LYRA Ticker-Specific Updates for Smart Investing
The Fly
13 days ago
MT Newswires
13 days ago
MT Newswires
14 days ago
GlobeNewswire
14 days ago
Simply Wall St.
18 days ago
Zacks
20 days ago
GlobeNewswire
20 days ago
GlobeNewswire
24 days ago